Senhwa Biosciences, Inc., a clinical-stage biopharmaceutical company focused on next generation DNA Damage Response therapeutics for the treatment of cancer, announced that the first patient has enrolled into an investigator-initiated trial of its investigational drug, Silmitasertib, as a treatment for hospitalized COVID-19 patients at Banner Health-University Medical Center in Phoenix, Arizona.
January 21, 2021
· 3 min read